A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 7, Issue , 2014, Pages 25-30

  Nardolillo, Anne Marie ^a   Kane, Michael P ^a   Busch, Robert S ^b   Watsky, Jay ^b   Hamilton, Robert A ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b LLP   (United States)

^c Albany College of Pharmacy and Health Sciences Vermont Campus ^*  (United States)

Author keywords

Canagliflozin; Invokana; SGLT 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; CIPROFLOXACIN; CREATININE; FLUCONAZOLE; HEMOGLOBIN A1C;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BALANITIS; BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPONATREMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POLYURIA; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA MYCOSIS; VERY ELDERLY; WEIGHT REDUCTION; YOUNG ADULT;

EID: 84907689729     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S18182     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014. http://www.cdc.gov/ diabetes/pubs/statsreport14.htm. Accessed June 13, 2014.
2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
4. American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37:S14–S80.
5. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007;24:350–358.
6. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443–453.
7. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277.
8. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2013;15:1–13.
9. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–950.
10. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
11. Gonzalez-Lavalle FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
12. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467–477.
13. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9):2137–2139.
14. Bell DS. The potent synergistic effects of the combination of liraglutie and canagliflozin on glycemic control and weight loss. Am J Case Rep. 2014;15: 152–154.
15. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014:1–10. [Epub ahead of print].
16. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1:140–151.
17. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
18. Polidori D1, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.